Research ArticleCancer

Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

See allHide authors and affiliations

Science Translational Medicine  11 Mar 2020:
Vol. 12, Issue 534, eaav7431
DOI: 10.1126/scitranslmed.aav7431

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Checkpoint musical chairs

Anti–PD-1 or PD-L1 antibodies can reinvigorate antitumor immunity in a subset of patients with cancer. To better understand the mechanisms behind successful therapy, Mayoux et al. characterized various ligands on the surface of dendritic cells (DCs). PD-L1 on DCs can bind B7.1 on the same cell, potentially preventing PD-1 ligation on T cells or B7.1 ligation of its partner CD28. They saw that PD-L1 was expressed in excess of B7.1, likely preventing T cell stimulation through these two pathways. Patients with a high DC signature before treatment were more likely to respond to PD-L1 blockade. These results reveal that in cis interactions on DCs have immunological and likely clinical consequences for checkpoint blockade therapy.

View Full Text

Stay Connected to Science Translational Medicine